Tim Shannon is a physician-turned-investor who trained as a pulmonary and critical care doctor before serving as CEO of publicly traded biotech company CuraGen and joining Canaan Partners. He served as founding CEO of Arvinas, helping to build one of the pioneering companies in targeted protein degradation, and frequently takes on board chair roles where he shapes scientific strategy and development plans rather than just providing capital.

• Deep interest in biotechnology advancements and clinical trial outcomes across various disease states. Focuses heavily on the science and regulatory hurdles, pointing out that establishing a clear therapeutic index is crucial for regulatory approval and market success. Highlights major breakthroughs as part of a new renaissance for drugs, specifically celebrating positive clinical results in areas like Alzheimer disease and the return of pharmaceutical focus to cardiovascular treatments.
• Fascination with the economic mechanisms driving the pharmaceutical industry, particularly drug pricing and payor incentives. Argues that high upfront costs for cures to diseases like Hepatitis C are sound investments because biosimilars and generics eventually lower long-term costs. Observes that the lack of new antibiotics is driven by poor pricing models and restricted use rather than a lack of scientific capability, and questions whether skewed regulatory incentives might cause common diseases to be neglected in favor of rare ones.
• Strong focus on the evolution of digital health platforms and the application of consumer technology in medicine. Advises digital health startups not to overlook pharmaceutical companies as potential customers. Emphasizes that for medical wearables to succeed, they must incorporate passive data tracking, timely user nudges, and clean design interfaces.
• Close attention to the financial health and public market performance of life science companies. Keeps a pragmatic view on market valuations and capital efficiency, noting that high cash burn rates following an initial public offering are a standard reality of the sector rather than a surprise. Cautions that mainstream media coverage of biotech market bubbles can trigger funding pullbacks, indicating a preference for founders who are realistic about capital requirements and long-term market cycles.